Compare Repligen Corporation Common Stock (RGEN) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Williams Companies Inc — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Williams Companies Inc trades at $72.47 (market cap $91.21B). The key difference: Williams Companies Inc is far larger — about 8.2× Repligen Corporation Common Stock's market cap, and Williams Companies Inc pays a 2.82% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Williams Companies Inc for 58 Days on average.
| RGEN | WMB | |
|---|---|---|
Market Cap | $11.14B | $91.21B |
Volume | 1,259,263 | 6,950,661 |
Sector | Health | Energy |
52-Week High | $194.57 | $79.40 |
52-Week Low | $102.87 | $56.51 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $11.02B | $121.84B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Williams Companies (WMB) trades at $72.80, down 1.85% on the day, with strong technical momentum indicated by bullish moving averages. The company maintains robust profitability with 25.18% net income margin and 24.02% ROE, supported by $5.9B operating cash flow in 2025. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 and Q2 2026 missed. The stock benefits from positive analyst sentiment with 79% buy ratings and $87.08 consensus price target, representing 20% upside potential.
WMB presents a compelling investment case with strong dividend growth, exposure to rising natural gas demand from AI data centers, and resilient midstream business model. Key risks include energy market volatility, high debt levels at $24.74B long-term debt, and execution challenges in capital-intensive projects. The stock's valuation at 29.71 P/E appears reasonable given growth prospects, but investors should monitor debt management and energy price sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
